A common antioxidant had no effect on lung function compared to a placebo in patients with a chronic, progressive respiratory disease, according to research led by Weill Cornell Medical College and the IPF Clinical Research Network. The findings on N-acetylcysteine (NAC), released today by the New England Journal of Medicine, are likely to prompt physicians to reconsider the best way to treat idiopathic pulmonary fibrosis (IPF), an incurable disease that often kills patients within a few years of their diagnosis.